NewcelX Ltd. (NCEL) vs Novartis AG (NVS)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| NCEL | NVS | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Size band | NANO | MEGA |
| Listing | Nasdaq CM | NYSE |
| Country | Switzerland | Switzerland |
| Theme | cell-therapy | pharmaceuticals-large-cap |
| Price and returns | ||
| Last close | $2.55 | $153.81 |
| Return · 1 week | −3.04% | +2.40% |
| Return · 1 month | −12.67% | +4.72% |
| Return · 3 months | −26.72% | −3.78% |
| Return · year to date | +22.01% | +14.40% |
| Return · 1 year | −79.44% | +22.73% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −85.22% | −9.77% |
| 52-week high | $17.25 | $170.46 |
| 52-week low | $1.83 | $121.57 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $14.73M | $292.35B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $14.15K | $264.76M |
| Employees | 9 | 75,267 |
| Valuation | ||
| Price to earnings · trailing | 4.81× | 22.75× |
| Price to earnings · forward | n/a (negative forward earnings) | 15.37× |
| Price to sales | — | 5.05× |
| Price to book | 2.23× | 6.89× |
| Enterprise value to EBITDA | n/a (negative value) | 14.20× |
| Enterprise value to revenue | — | 5.79× |
| PEG ratio | — | 3.53 |
| Earnings per share · trailing | 0.52 | 6.62 |
| Profitability | ||
| Gross margin | — | 74.74% |
| Operating margin | 0.00% | 34.62% |
| Profit margin | — | 22.50% |
| Return on equity | — | 30.35% |
| Return on assets | −49.59% | 10.25% |
| Growth | ||
| Revenue growth | — | +0.80% |
| Earnings growth | — | −17.00% |
| Balance sheet and payout | ||
| Debt / equity (%) | 6.49 | 116.85 |
| Current ratio | 0.40 | 0.86 |
| Dividend yield | 0.00% | 3.15% |
| Payout ratio | 0.00% | 71.60% |
| Trend and volatility | ||
| RSI · 14 | 41.57 | 61.14 |
| ADX · 14 | 9.25 | 18.61 |
| 50-day average | $3.08 | $148.17 |
| 200-day average | $3.10 | $151.49 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 13.86% | 1.93% |
The full NCEL analysis
Everything this table leaves out for NewcelX Ltd.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NCEL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NCEL analysisThe full NVS analysis
Everything this table leaves out for Novartis AG: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NVS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NVS analysis